Non-personal information is information we collect through this website that does not identify you as an individual person. It includes any of the following types of information:
Because non-personal information cannot identify you or be tied to you in any way, there are few restrictions on the ways that we can use or share non-personal information. Primarily, we will use this data to make enhancements to the website that are specifically tailored to improve the experience of the user community. One way that we use non-personal information is to demonstrate user trends on the website. Often, this is done by aggregating the data gleaned from non-personal information. This aggregated, de-identified data might be shared with outside parties who are employed to implement improvements to the site.
Personal information is information we collect through this website that we can use to specifically identify you, such as your:
We comply with applicable privacy laws in the collection, storage, and use of your personal information. When you submit personal information through this website you are giving us permission to use your personal information for the purpose described below. Your information will never be shared with a third party, except as outlined below.
We may keep and use personal information we collect from you through this website to provide you with access to this website. In addition, we may keep and use your personal information:
Information Collection Specific to PEER Network
What Information is Collected?
We collect contact information, including your first name and first initial of your last name, e-mail, phone number(s), and state of residence. We also collect your age range, gender, the name of the physician who treats you for pulmonary arterial hypertension (PAH), and what UTC products (if any) you are currently receiving to treat your PAH. We ask you to indicate if you are a patient or caregiver and the purpose for choosing a PEER Mentor. Finally, we ask you to choose a User Name and password. From time to time, we also ask that you respond to surveys, which help to evaluate your satisfaction with the program.
How the Information is Used
We respect the information you submit. Your information will be used only for internal program monitoring. This may include looking at trends regarding current or planned UTC product use and discontinuation. Program staff will also use survey data to monitor trends in website user attitudes toward and satisfaction with the program. This includes average response time of Mentors, whether you might recommend this program to others, and your suggestions as to how we might improve the program.
We will never tie your name with your other personal information in our reporting and evaluation of the program. We will not use, sell, or assign your personal information for any purpose other than to communicate with you about the PEER Network, and to administer the PEER Network.
Your password will be used to keep your information secure and help us build your personalized webpage when you login.
Your age range, gender, User Name, and why you are seeking a Mentor will be shared with your Mentor. This information will help your Mentor better understand your circumstances and provide you with a meaningful experience.
In the ordinary course of business, we may share some of your personal information with companies that we hire to perform services or functions on our behalf as necessary to administer the PEER Network. For example, we employ a company to develop and maintain this website. In this case, the company will have access to your personal information in the ordinary course of business. However, in this instance, and all instances in which your personal information is shared with a third party, we will not authorize them to keep, disclose, or use your information with others except for the purpose of providing the services we asked them to provide.
We may be legally compelled to release your personal information in response to a court order, subpoena, search warrant, law, or regulation. We may cooperate with law enforcement authorities in investigating and prosecuting website visitors who violate our rules or engage in behavior which is harmful to other visitors (or illegal).
We may disclose your personal information to third parties if we feel that the disclosure is necessary to:
Once you register through this website, we may contact you periodically by e-mail, mail, or telephone to administer the PEER Network. Additionally, if you ask a question or otherwise initiate a communication and request a response from us, we will send you a response via e-mail, mail, or telephone. Our response may include your personal information, including personal information about your health, your name, address, etc. We cannot guarantee that our e-mails to you will be secure from unauthorized interception.
We care about protecting the online privacy of children. This website is not intended for use by children under the age of 18. We will not intentionally collect any personal information (such as a child's name or e-mail address) from children under the age of 18. If you are a child under age 18, please do not send us any information about yourself. If you think that we have collected personal information from a child under the age of 18, please contact us so that we can take appropriate remedial action.
We take reasonable steps to protect your personal information from loss, misuse, and unauthorized access, disclosure, alteration, or destruction. You should keep in mind that no Internet transmission is ever 100% secure or error-free. Data you submit to this website, and information sent to or from us or you by e-mail or over the Internet and this website may not be secure, and you should therefore take special care in deciding what information you send to us via e-mail.
THE PEER NETWORK IS INTENDED FOR US AUDIENCES ONLY. If you are located outside of the United States, please consult with your local physician or pharmacy for information about Orenitram® (treprostinil) Extended-Release Tablets, Tyvaso® (treprostinil) Inhalation Solution, or Remodulin® (treprostinil) Injection. The Full Prescribing Information for these products is listed below.
Call your healthcare provider for medical advice about side effects. You are encouraged to report negative side effects to the FDA at www.fda.gov/medwatch or call 1-800-FDA-1088.
Orenitram is a prescription medicine used to treat pulmonary arterial hypertension (PAH) which is high blood pressure in the arteries of your lungs. Orenitram may improve your ability to exercise. It is not known if Orenitram is safe and effective in children under 18 years of age.
Do not take Orenitram if you have severe liver problems.
Before you take Orenitram, tell your healthcare provider if you:
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Orenitram and other medicines may affect each other causing side effects. Do not start or stop any new medicine until you check with your healthcare provider. Especially tell your healthcare provider if you take another medicine that contains the same ingredient, treprostinil. Know the medicines you take. Keep a list of them and the dose you take to show to your healthcare provider and pharmacist when you get a new medicine.
Do not change your dose or suddenly stop taking Orenitram without first talking to your healthcare provider. Stopping Orenitram suddenly may cause worsening of your PAH symptoms. If you miss two or more doses of Orenitram, call your healthcare provider. If you take too much Orenitram, call your healthcare provider or go to the nearest hospital emergency room right away.
If Orenitram tablets are not taken whole, they may release too much medicine at one time. This can lead to side effects. Do not split, chew, crush, or break your Orenitram tablets. Do not take Orenitram tablets that are damaged or broken. Take Orenitram with food.
Orenitram can cause serious side effects, including an increased risk of bleeding. This risk could be increased if you are taking blood thinners such as warfarin.
The most common side effects of Orenitram include headache, diarrhea, nausea and flushing. These are not all of the possible side effects of Orenitram. Tell your doctor about any side effects that bother you, get worse over time, or do not go away.
For more information about Orenitram, visit www.orenitram.com. Questions? Call 1-877-UNITHER (1-877-864-8437).
Tyvaso is a prescription medicine used in adults to treat pulmonary arterial hypertension (PAH) (WHO Group 1), which is high blood pressure in the arteries of your lungs. Tyvaso can improve exercise ability in people who also take bosentan (an endothelin receptor antagonist, (ERA)) or sildenafil (a phosphodiesterase-5 (PDE-5) inhibitor). Your ability to do exercise decreases 4 hours after taking Tyvaso.
The effects of Tyvaso are unknown in patients under 18 years of age.
Before you take Tyvaso, tell your healthcare provider about all of your medical conditions, including if you:
It is important to tell your healthcare provider about all the medicines you may be taking, including prescription and non-prescription medicines, vitamins, and herbal supplements, as they may affect your use of Tyvaso by increasing the risk of side effects or decreasing effectiveness. Especially tell your healthcare provider if you take any of these medicines:
The most common side effects of Tyvaso are coughing, headache, throat irritation and pain, nausea, reddening of the face and neck (flushing), and fainting or loss of consciousness. These are not all the possible side effects of Tyvaso. Tell your healthcare provider about any side effects that bother you or do not go away. Your healthcare provider may be able to help you manage the side effects.
For more information about Tyvaso, visit www.tyvaso.com. Questions? Call 1-877-UNITHER (1-877-864-8437).
Remodulin is a prescription medication used in adults with pulmonary arterial hypertension (PAH; WHO Group 1), to diminish symptoms associated with exercise. PAH is high blood pressure in the arteries of your lungs. Remodulin was studied mainly in patients with NYHA Functional Class II-IV symptoms. Remodulin is delivered (infused) continuously using a pump connected to a small tube that is either placed under the skin (subcutaneously [SC]) or inserted into a vein in the upper chest (intravenously [IV]). Because there are risks associated with continuous IV infusion, such as serious blood stream infections, IV infusion should be reserved for people who cannot tolerate SC infusion or for those in whom the risks are considered acceptable.
In patients with PAH who need to switch from Flolan® (epoprostenol sodium), Remodulin is approved to slow the worsening of symptoms. The risks and benefits of each drug should be carefully considered before switching.
Please see the Full Prescribing Information for Remodulin.
For more information about Remodulin, visit www.remodulin.com. Questions? Call 1-877-UNITHER (1-877-864-8437).
Orenitram, Tyvaso, and Remodulin are registered trademarks of United Therapeutics Corporation.
All other brands are trademarks of their respective owners. The makers of these brands are not affiliated with and do not endorse United Therapeutics or its products.